Key result
ADRB1 Arg389Arg genotype linked to ~10 mmHg greater SBP drop with bisoprolol in ACS.
Why the study?
To investigate whether beta1-adrenergic receptor (ADRB1) polymorphisms are associated with response to bisoprolol treatment in beta-blocker naive patients with ACS.
Does the ADRB1 Arg389Gly polymorphism predict blood pressure and heart rate response to bisoprolol in beta-blocker naive patients with acute coronary syndrome?
Cohort (n=77)
Double-blind
No
Does the ADRB1 Arg389Gly polymorphism predict blood pressure and heart rate response to bisoprolol in beta-blocker naive patients with acute coronary syndrome?
Mean Difference: -9.6 (95% CI -10.5–-8.7)
Absolute Event Rate: -8.5% vs -0.76%
p-value: p=0.00012
The ADRB1 Arg389Gly polymorphism may serve as a useful genetic predictor of blood pressure response to bisoprolol in patients with acute coronary syndrome.
May identify enhanced BP responders to bisoprolol in ACS; hypothesis-generating and requires prospective validation before clinical use.
Aim: To investigate the association between beta1-adrenergic receptor (ADRB1) polymorphisms and response to bisoprolol treatment in beta-blocker naive patients with acute coronary syndrome (ACS). Patients & methods: Seventy-seven patients received bisoprolol for four weeks. Blood pressure and heart rate were measured at baseline and during treatment. TaqMan allelic discrimination method was utilized for ADRB1 Ser49Gly and Arg389Gly genotyping. Results: Arg389Arg carriers showed greater reductions in systolic and diastolic blood pressure (-8.5% ± 7.8% vs -0.76% ± 8.7%, p = 0.000218), and (-9.5% ± 9.7% vs -0.80% ± 11.5%, p = 0.000149), respectively, compared with Gly389 carriers. No statistical difference was found for study's outcomes based on codon 49. Conclusion: Arg389Gly polymorphism is a promising bisoprolol response predictor in ACS patients.
No takes yet. Share an insight, caveat, or question.
Fayed et al. (2023) conducted a cohort in Acute coronary syndrome (n=77). ADRB1 Arg389Arg genotype vs. Gly389 carriers was evaluated on Reduction in systolic blood pressure (MD -9.6 mm Hg, 95% CI -10.5 to -8.7, p=0.00012). In beta-blocker-naive patients with acute coronary syndrome treated with bisoprolol, the ADRB1 Arg389Arg genotype was associated with a significantly greater reduction in systolic blood pressure compared with Gly389 carriers (MD -9.6 mm Hg).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: